Stock Events

Abeona Therapeutics 

$5.06
61
-$0.22-4.17% Friday 15:46

Statistics

Day High
5.11
Day Low
5.04
52W High
8.8
52W Low
2.35
Volume
131
Avg. Volume
1,007
Mkt Cap
14.14B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

15MayConfirmed
Q2 2022
Q3 2022
Q4 2022
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-2.08
-0.88
0.32
1.52
Expected EPS
-0.53
Actual EPS
-1.16

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0H7R.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.96B
Biogen focuses on developing therapies for neurological and neurodegenerative diseases, directly competing with Abeona's gene therapy approach for similar disorders.
Pfizer
PFE
Mkt Cap169.83B
Pfizer has a broad portfolio including gene therapies targeting rare diseases, overlapping with Abeona's focus areas.
Sangamo Therapeutics
SGMO
Mkt Cap82.4M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the same space as Abeona for genetic disorders.
Biomarin Pharmaceutical
BMRN
Mkt Cap15.97B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for rare diseases, directly competing with Abeona's rare disease focus.
Bluebird bio
BLUE
Mkt Cap114.8M
bluebird bio focuses on gene therapies for genetic diseases and cancer, competing in the gene therapy space with Abeona.
Ultragenyx Pharmaceutical
RARE
Mkt Cap3.54B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its drug development, similar to Abeona's focus.
Sarepta Therapeutics
SRPT
Mkt Cap13.76B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics and gene therapy for rare diseases, competing with Abeona's gene therapy approach.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.85B
Vertex Pharmaceuticals engages in developing therapies for treating cystic fibrosis and other serious diseases, competing in the rare disease market with Abeona.
Novo Nordisk
NVO
Mkt Cap445.94B
Novo Nordisk focuses on a broad range of treatments including for rare diseases, potentially competing with Abeona in the gene therapy and rare disease market.

About

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Show more...
CEO
Dr. Vishwas Seshadri M.B.A., Ph.D.
Employees
84
Country
US
ISIN
US00289Y2063
WKN
000A3DMHM

Listings